# Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia

> **NCT01056523** · PHASE1,PHASE2 · COMPLETED · sponsor: **Jewish General Hospital** · enrollment: 29 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Ribavirin
- **DRUG:** Cytarabine arabinoside

## Key facts

- **NCT ID:** NCT01056523
- **Lead sponsor:** Jewish General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01056523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01056523, "Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01056523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*